Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

134.88 +2.82 (+2.14%)
Official Closing Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,636,695
Open 134.66
Bid (Size) 133.77 (2)
Ask (Size) 134.98 (1)
Prev. Close 132.06
Today's Range 133.63 - 135.20
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. The telehealth... 
Via Benzinga
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga

Performance

YTD
+32.09%
+32.09%
1 Month
-0.27%
-0.27%
3 Month
-4.33%
-4.33%
6 Month
+3.47%
+3.47%
1 Year
+44.22%
+44.22%

More News

Read More
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Via The Motley Fool
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Via Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,700 Today
Via Benzinga
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
Via Benzinga
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
Novo Nordisk Unusual Options Activity
Via Benzinga
Why Roche Holdings Stock Withered on Wednesday
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
Via The Motley Fool
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
Via Benzinga
Is Hims & Hers Health the Next Teladoc?
Via The Motley Fool
Exposures COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Via Benzinga
Exposures Product Safety
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Via MarketBeat
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Via The Motley Fool
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Via Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.